Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Unknown 1Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 19Thoracic 4Genitourinary 3Dermatologic 3Other solid neoplasm 1Lymphoid 1Gynecologic 1Endocrine 1Breast 1

Conditions

Melanoma 273Carcinoma, Non-Small-Cell Lung 49Carcinoma, Renal Cell 37Uveal Melanoma 23Skin Neoplasms 23Neoplasm Metastasis 23Colorectal Neoplasms 22Carcinoma, Transitional Cell 20Carcinoma, Merkel Cell 20Squamous Cell Carcinoma of Head and Neck 19Neoplasms 18Lung Neoplasms 17Carcinoma, Hepatocellular 16Brain Neoplasms 16Triple Negative Breast Neoplasms 14Uterine Cervical Neoplasms 13Ovarian Neoplasms 13Stomach Neoplasms 12Urinary Bladder Neoplasms 10Small Cell Lung Carcinoma 10Head and Neck Neoplasms 9Lymphoma 8Carcinoma, Basal Cell 8Pancreatic Neoplasms 7Esophageal Neoplasms 7Breast Neoplasms 7Kidney Neoplasms 6Sarcoma 5Prostatic Neoplasms 5Hodgkin Disease 5

Interventions

pembrolizumab 4Cyclophosphamide 4fludarabine 3Nivolumab 3Ipilimumab 3Drug Therapy 3aldesleukin 2Biopsy 2utomilumab 1trastuzumab deruxtecan 1sargramostim 1poly ICLC 1liposomal doxorubicin 1fludarabine phosphate 1erythromycin propionate-N-acetylcysteinate 1enzalutamide 1durvalumab 1brodalumab 1atezolizumab 1advexin 1Sirolimus 1Radiotherapy, Conformal 1Quality of Life 1Psychology, Positive 1Poly I-C 1Patient Reported Outcome Measures 1Observation 1National Cancer Institute (U.S.) 1Molecular Diagnostic Techniques 1Microscopy, Electron 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Liver Neoplasms × Nivolumab × Dermatologic × Clear all
NCT06362369 2026-04-13

A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

7 Hills Pharma, LLC

Phase 1/2 Recruiting
126 enrolled
DermatologicGastrointestinalGenitourinaryOther solid neoplasmThoracic

Turcot syndrome, Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Kidney Neoplasms, Liver Neoplasms, Melanoma, Neoplasm Metastasis, Skin Neoplasms, Colorectal Neoplasms

NCT04311710 2023-02-24

CheckMate 76U

Bristol-Myers Squibb

Phase 1 Terminated
21 enrolled
DermatologicGastrointestinalGenitourinaryThoracic

Urinary Bladder Neoplasms, Kidney Neoplasms, Liver Neoplasms, Lung Neoplasms, Neoplasms, Skin Neoplasms

NCT03544723 2020-06-09

Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.

MultiVir, Inc.

Phase 2 Unknown
40 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicLymphoidThoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Hodgkin Disease, Liver Neoplasms, Lymphoma, Melanoma, Stomach Neoplasms, Carcinoma, Merkel Cell, Neoplasms, Squamous Cell, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡